Venous Leg Ulcer Treatment Market to Reach $4.84 Billion by 2026; Recent Advancements in Treatment Options Associated with the Disorder Will Aid Growth

The global venous leg ulcer treatment market size is projected to reach USD 4.84 billion by 2026. Recent advancements in treatment options for venous leg ulcer will have a positive impact on the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Venous Leg Ulcer Treatment (VLU) Market Size, Share and Global Trend by Product (Compression Therapy, Advanced Wound Dressings, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), and Regional Forecast, till 2026,” the market was worth USD 2.95 billion in 2018 and will exhibit a CAGR of 6.4% during the forecast period, 2019-2026.

Venous leg ulcer is a serious and long lasting disorder that occurs in the inside of the leg. The disorder can be cause after a minor injury or accident wherein a high pressure to the veins damages the skin. The high prevalence of the disease has created a huge emphasis on the research and development, subsequently attracting huge investment from large scale companies. According to the National Health Service, venous leg ulcer is the most common type of leg ulcers. It accounts for around 90% of the total ulcers in the world. Moreover, venous leg ulcer affects 1 in every 500 people in the UK. Such high prevalence of the disease will emerge in favor of the companies operating in the market. The increasing prevalence of the disease will have a positive impact on the growth of the market in the coming years.

3M’s acquisition of Acelity is a Major Highlight of Recent Years

The report highlights a few of the major industry developments of recent times and gauges their impact on the market. With a bid to capitalizing on the current scenario of the market, which includes limited treatment options, several companies are looking to acquire smaller and medium enterprises. In October 2019, 3M announced that it has completed the acquisition of Acelity along with its KCI subsidiaries. Through this acquisition, the company plans to enhance its portfolio of surgical wound treatment offerings and subsequently establish a stronghold in the market. 3M’s latest acquisition will not only benefit the company, but will have a positive impact on the growth of the market in the forthcoming years.

To Get the detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/venous-leg-ulcer-vlu-treatment-market-102370

Advancements in Treatment Options to Create Several Growth Opportunities

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the advancements in venous leg ulcer treatment options has made the highest impact on the growth of the market. Conventional treatment methods have been replaced by pressure therapies, which have further allowed for better operational efficacies. The increasing investment in the development of newer products has contributed to the advancements in the treatment methods associated with the disease.

Large Scale Companies Have Identified Mergers and Acquisitions as the Leading Strategy

The presence of several large scale companies has created a healthy competition in the market in recent years. With a bid to establishing a stronghold in such a competitive market, several companies are looking to adopt mergers and acquisitions as the leading strategy. A few of the leading companies that are currently operating in the market include:

• Integra Lifesciences


• Smith & Nephew


• Coloplast Corp.


• URGO


• 3M


• Paul Hartmann


• Bauerfeind


• Cardinal Health


• SIGVARIS GROUP


• KCI Licensing, Inc.


• Other Players

Further Report Findings:

• The report analyses ongoing venous leg ulcer treatment market trends across five major regions:

• 
  
  
  
  • Europe (Largest)
    
    
    
    • 2017: USD 950.8 Million
    
    
    • 2018: USD 1001.8 Million
    
    
    
    
  
  
  • North America (Likely to emerge leading)
  
  
  • Asia Pacific
  
  
  • Latin America
  
  
  • Middle East and Africa
  
  
  
  

• Besides regional demographics, the market is segmented on the basis of product and end-user

Industry Developments:

• October 2019: PolarityTE, Inc. announces a new pilot study data of SkinTE that is used for treatment of venous stasis leg ulcer.

The global venous leg ulcer treatment market is segmented on the basis of: